Paper3936557
Selective killing of carcinoma cells "in vitro" by lipophilic-cationic compounds: a cellular basis.
Lampidis TJ and 3 others. Biomed Pharmacother, 1985. Cited by 86 papers, by iCite.
Cite this record
ConductScience Library. Selective killing of carcinoma cells "in vitro" by lipophilic-cationic compounds: a cellular basis. Papers, record 3936557. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3936557
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Selective killing of carcinoma cells "in vitro" by lipophilic-cationic compounds: a cellular basis.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Membrane Potentials | Major topic |
| Onium Compounds | Major topic |
| Organophosphorus Compounds | Major topic |
| Phenazines | Major topic |
| Rhodamines | Major topic |
| Xanthenes | Major topic |
| Animals | |
| Breast Neoplasms | |
| Cell Line | |
| Female | |
| Haplorhini | |
| HeLa Cells | |
| Humans | |
| Kidney | |
| Marsupialia |
Source PubMed
Cited by27
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 86 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40524980 | Triphenylphosphine-Based Mitochondrial Targeting Nanocarriers: Advancing Cancer Therapy. | Clin Pharmacol | 2025 | https://conductscience.org/library/papers/40524980 | PubMed |
| 39275091 | The ATTO 565 Dye and Its Applications in Microscopy. | Molecules | 2024 | https://conductscience.org/library/papers/39275091 | PubMed |
| 38116415 | A Neutral Flavin-Triphenylamine Probe for Mitochondrial Bioimaging under Different Microenvironments. | ACS Med Chem Lett | 2023 | https://conductscience.org/library/papers/38116415 | PubMed |
| 37888013 | Toxic Effects of Penetrating Cations. | Membranes (Basel) | 2023 | https://conductscience.org/library/papers/37888013 | PubMed |
| 36559149 | Mitochondrial Dysfunction: Pathophysiology and Mitochondria-Targeted Drug Delivery Approaches. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36559149 | PubMed |
| 34135584 | Novel Strategies for Disrupting Cancer-Cell Functions with Mitochondria-Targeted Antitumor Drug-Loaded Nanoformulations. | Int J Nanomedicine | 2021 | https://conductscience.org/library/papers/34135584 | PubMed |
| 33114695 | Mitocans Revisited: Mitochondrial Targeting as Efficient Anti-Cancer Therapy. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/33114695 | PubMed |
| 32705265 | Mechanistic investigations of antitumor activity of a Rhodamine B‑oleanolic acid derivative bioconjugate. | Oncol Rep | 2020 | https://conductscience.org/library/papers/32705265 | PubMed |
| 30505656 | Mitochondria-targeting drug conjugates for cytotoxic, anti-oxidizing and sensing purposes: current strategies and future perspectives. | Acta Pharm Sin B | 2018 | https://conductscience.org/library/papers/30505656 | PubMed |
| 30428319 | Mitochondria-Targeted Honokiol Confers a Striking Inhibitory Effect on Lung Cancer via Inhibiting Complex I Activity. | iScience | 2018 | https://conductscience.org/library/papers/30428319 | PubMed |
| 30174604 | Mitochondrial-Targeting Anticancer Agent Conjugates and Nanocarrier Systems for Cancer Treatment. | Front Pharmacol | 2018 | https://conductscience.org/library/papers/30174604 | PubMed |
| 28654243 | Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications. | Chem Rev | 2017 | https://conductscience.org/library/papers/28654243 | PubMed |
| 24622277 | Rosamines targeting the cancer oxidative phosphorylation pathway. | PLoS One | 2014 | https://conductscience.org/library/papers/24622277 | PubMed |
| 24518045 | Actively targeted in vivo multiplex detection of intrinsic cancer biomarkers using biocompatible SERS nanotags. | Sci Rep | 2014 | https://conductscience.org/library/papers/24518045 | PubMed |
| 24059469 | Tunable cytotoxicity of rhodamine 6G via anion variations. | J Am Chem Soc | 2013 | https://conductscience.org/library/papers/24059469 | PubMed |
| 23210516 | Effect of the prosthetic group on the pharmacologic properties of 18F-labeled rhodamine B, a potential myocardial perfusion agent for positron emission tomography (PET). | J Med Chem | 2012 | https://conductscience.org/library/papers/23210516 | PubMed |
| 22991065 | Role of cytokines in experimentally induced lung cancer and chemoprevention by COX-2 selective inhibitor, etoricoxib. | Mol Cell Biochem | 2013 | https://conductscience.org/library/papers/22991065 | PubMed |
| 20346876 | Biodistribution and stability studies of [18F]fluoroethylrhodamine B, a potential PET myocardial perfusion agent. | Nucl Med Biol | 2010 | https://conductscience.org/library/papers/20346876 | PubMed |
| 19995573 | Small mitochondria-targeting molecules as anti-cancer agents. | Mol Aspects Med | 2010 | https://conductscience.org/library/papers/19995573 | PubMed |
| 19783150 | Synthesis of fluorine-18 labeled rhodamine B: A potential PET myocardial perfusion imaging agent. | Appl Radiat Isot | 2010 | https://conductscience.org/library/papers/19783150 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3936557
GET https://conductscience.org/api/papers/v1/3936557/cited_by?page=2